Virtual screening with flexible docking and COMBINE-based models. Application to a series of factor Xa inhibitors.
暂无分享,去创建一个
[1] Sung-Hou Kim,et al. Structural basis for chemical inhibition of human blood coagulation factor Xa. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[2] R. Leadley. Coagulation factor Xa inhibition: biological background and rationale. , 2001, Current topics in medicinal chemistry.
[3] L. Chi,et al. Recent advances in clinical trials of the direct and indirect selective Factor Xa inhibitors , 2000, Expert opinion on investigational drugs.
[4] A. N. Jain,et al. Hammerhead: fast, fully automated docking of flexible ligands to protein binding sites. , 1996, Chemistry & biology.
[5] D. Agrafiotis,et al. Combinatorial informatics in the post-genomics era , 2002, Nature Reviews Drug Discovery.
[6] Hans Matter,et al. Design and quantitative structure-activity relationship of 3-amidinobenzyl-1H-indole-2-carboxamides as potent, nonchiral, and selective inhibitors of blood coagulation factor Xa. , 2002, Journal of medicinal chemistry.
[7] P. Kollman,et al. A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules , 1995 .
[8] Ajay N. Jain. Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. , 2003, Journal of medicinal chemistry.
[9] Christopher W. Murray,et al. The sensitivity of the results of molecular docking to induced fit effects: Application to thrombin, thermolysin and neuraminidase , 1999, J. Comput. Aided Mol. Des..
[10] Biserka Kojić-Prodić,et al. A quantitative model for predicting enzyme enantioselectivity: application to Burkholderia cepacia lipase and 3-(aryloxy)-1,2-propanediol derivatives. , 2002, Journal of molecular graphics & modelling.
[11] Ferran Sanz,et al. 3D-QSAR methods on the basis of ligand–receptor complexes. Application of COMBINE and GRID/GOLPE methodologies to a series of CYP1A2 ligands , 2000, J. Comput. Aided Mol. Des..
[12] K Fujikawa,et al. The coagulation cascade: initiation, maintenance, and regulation. , 1991, Biochemistry.
[13] A. Spada,et al. Crystal structures of human factor Xa complexed with potent inhibitors. , 2000, Journal of medicinal chemistry.
[14] V. Mikol,et al. The use of 3D structural data in the design of specific factor Xa inhibitors. , 2001, Current topics in medicinal chemistry.
[15] A. Ortiz,et al. Evaluation of docking functions for protein-ligand docking. , 2001, Journal of medicinal chemistry.
[16] F. Javier Luque,et al. Ligand-induced changes in the binding sites of proteins , 2002, Bioinform..
[17] Daniel L Cheney,et al. Optimization of the beta-aminoester class of factor Xa inhibitors. Part 2: Identification of FXV673 as a potent and selective inhibitor with excellent In vivo anticoagulant activity. , 2002, Bioorganic & medicinal chemistry letters.
[18] J R Pruitt,et al. Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 1. , 1999, Journal of medicinal chemistry.
[19] D L Cheney,et al. Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa. , 1999, Journal of medicinal chemistry.
[20] Jonas Boström,et al. Reproducing the conformations of protein-bound ligands: A critical evaluation of several popular conformational searching tools , 2001, J. Comput. Aided Mol. Des..
[21] W R Ewing,et al. The design of competitive, small-molecule inhibitors of coagulation factor Xa. , 2001, Current topics in medicinal chemistry.
[22] D. R. Holland,et al. Rational design, synthesis, and biological activity of benzoxazinones as novel factor Xa inhibitors. , 2000, Journal of medicinal chemistry.
[23] Gisbert Schneider,et al. Virtual screening and fast automated docking methods. , 2002, Drug discovery today.
[24] Osvaldo Olmea,et al. MAMMOTH (Matching molecular models obtained from theory): An automated method for model comparison , 2002, Protein science : a publication of the Protein Society.
[25] G. Klebe,et al. Approaches to the Description and Prediction of the Binding Affinity of Small-Molecule Ligands to Macromolecular Receptors , 2002 .
[26] M Pastor,et al. Comparative binding energy (COMBINE) analysis of human neutrophil elastase inhibition by pyridone-containing trifluoromethylketones. , 2001, Combinatorial chemistry & high throughput screening.
[27] Rowland Rs. Using X-ray crystallography in drug discovery. , 2002 .
[28] M. Whitlow,et al. Design, synthesis, and in vitro biological activity of indole-based factor Xa inhibitors. , 2000, Bioorganic & medicinal chemistry letters.
[29] Natasja Brooijmans,et al. Molecular recognition and docking algorithms. , 2003, Annual review of biophysics and biomolecular structure.
[30] M Pastor,et al. Comparative binding energy analysis of HIV-1 protease inhibitors: incorporation of solvent effects and validation as a powerful tool in receptor-based drug design. , 1998, Journal of medicinal chemistry.
[31] M Pastor,et al. Simulation of alternative binding modes in a structure-based QSAR study of HIV-1 protease inhibitors. , 1997, Journal of molecular graphics & modelling.
[32] Marcel L. Verdonk,et al. Sensitivity of molecular docking to induced fit effects in influenza virus neuraminidase , 2002, J. Comput. Aided Mol. Des..
[33] R C Wade,et al. Nuclear receptor-DNA binding specificity: A COMBINE and Free-Wilson QSAR analysis. , 2000, Journal of medicinal chemistry.
[34] Quan Ml,et al. The design and synthesis of noncovalent factor Xa inhibitors. , 2001 .
[35] R. Wexler,et al. The design and synthesis of noncovalent factor Xa inhibitors. , 2001, Current topics in medicinal chemistry.
[36] John A. Nelder,et al. A Simplex Method for Function Minimization , 1965, Comput. J..
[37] Thomas Lengauer,et al. Evaluation of the FLEXX incremental construction algorithm for protein–ligand docking , 1999, Proteins.
[38] Gerhard Klebe,et al. Comparison of Automatic Three-Dimensional Model Builders Using 639 X-ray Structures , 1994, J. Chem. Inf. Comput. Sci..
[39] Jonathan W. Essex,et al. A review of protein-small molecule docking methods , 2002, J. Comput. Aided Mol. Des..
[40] G. Klebe,et al. Knowledge-based scoring function to predict protein-ligand interactions. , 2000, Journal of molecular biology.
[41] R. Wade,et al. Comparative binding energy (COMBINE) analysis of influenza neuraminidase-inhibitor complexes. , 2001, Journal of medicinal chemistry.
[42] Pierre Baldi,et al. Assessing the accuracy of prediction algorithms for classification: an overview , 2000, Bioinform..
[43] M Pastor,et al. Reliability of comparative molecular field analysis models: effects of data scaling and variable selection using a set of human synovial fluid phospholipase A2 inhibitors. , 1997, Journal of medicinal chemistry.
[44] P. Lam,et al. Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa. , 2001, Journal of medicinal chemistry.
[45] S. Wold,et al. The Collinearity Problem in Linear Regression. The Partial Least Squares (PLS) Approach to Generalized Inverses , 1984 .
[46] Sébastien Maignan,et al. Molecular structures of human factor Xa complexed with ketopiperazine inhibitors: preference for a neutral group in the S1 pocket. , 2003, Journal of medicinal chemistry.
[47] Ting Wang,et al. Comparative binding energy (COMBINE) analysis of OppA-peptide complexes to relate structure to binding thermodynamics. , 2002, Journal of medicinal chemistry.
[48] J A McCammon,et al. Accommodating protein flexibility in computational drug design. , 2000, Molecular pharmacology.
[49] Eamonn F. Healy,et al. Development and use of quantum mechanical molecular models. 76. AM1: a new general purpose quantum mechanical molecular model , 1985 .
[50] R. Wade,et al. Prediction of drug binding affinities by comparative binding energy analysis. , 1997, Journal of medicinal chemistry.
[51] Joseph J. Barchi,et al. New Paradigms in Drug Design and Discovery , 2004 .
[52] Meir Glick,et al. Docking of flexible molecules using multiscale ligand representations. , 2002, Journal of medicinal chemistry.
[53] P. Kollman,et al. Atomic charges derived from semiempirical methods , 1990 .
[54] Gennady M Verkhivker,et al. Exploring the energy landscapes of molecular recognition by a genetic algorithm: analysis of the requirements for robust docking of HIV-1 protease and FKBP-12 complexes. , 1996, Proteins.
[55] P Willett,et al. Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.
[56] R. Rowland. Using X-ray crystallography in drug discovery. , 2002, Current opinion in drug discovery & development.
[57] J. Gasteiger,et al. FROM ATOMS AND BONDS TO THREE-DIMENSIONAL ATOMIC COORDINATES : AUTOMATIC MODEL BUILDERS , 1993 .
[58] Sung-Hou Kim,et al. Preparation, characterization, and the crystal structure of the inhibitor ZK-807834 (CI-1031) complexed with factor Xa. , 2000, Biochemistry.
[59] P. Kollman,et al. How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules? , 2000 .
[60] G J Williams,et al. The Protein Data Bank: a computer-based archival file for macromolecular structures. , 1978, Archives of biochemistry and biophysics.
[61] James J. P. Stewart,et al. MOPAC: A semiempirical molecular orbital program , 1990, J. Comput. Aided Mol. Des..
[62] I. Kuntz,et al. Flexible ligand docking: A multistep strategy approach , 1999, Proteins.
[63] R. Knabb,et al. Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 2. , 1999, Journal of Medicinal Chemistry.
[64] R C Wade,et al. Comparative binding energy analysis of the substrate specificity of haloalkane dehalogenase from Xanthobacter autotrophicus GJ10. , 2001, Biochemistry.
[65] J Andrew McCammon,et al. Protein flexibility and computer-aided drug design. , 2003, Annual review of pharmacology and toxicology.
[66] J. A. Kyle,et al. Structure-based design of potent, amidine-derived inhibitors of factor Xa: evaluation of selectivity, anticoagulant activity, and antithrombotic activity. , 2000, Journal of Medicinal Chemistry.
[67] S. Buchanan. Structural genomics: bridging functional genomics and structure-based drug design. , 2002, Current opinion in drug discovery & development.
[68] J. Venter,et al. Sequencing the entire genomes of free-living organisms: the foundation of pharmacology in the new millennium. , 2000, Annual review of pharmacology and toxicology.
[69] Ruth Nussinov,et al. Principles of docking: An overview of search algorithms and a guide to scoring functions , 2002, Proteins.
[70] Y. Hosaka,et al. Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as a factor Xa inhibitor II. Substituent effect on biological activities. , 2002, Chemical & pharmaceutical bulletin.